An Overview on a new generation LDL-C lowering drug: Inclisiran and its market forecast
1 Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, Hamdard Nagar, New Delhi – 110062, India.
2 Department of Cardiology, Fortis Heart Institute, New Delhi -110025, India.
3 Department of Engineering Program, College of Applied studies, University of Bahrain, Bahrain.
4 Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, Hamdard Nagar, New Delhi – 110062, India.
Review
World Journal of Biology Pharmacy and Health Sciences, 2024, 18(03), 180–185.
Article DOI: 10.30574/wjbphs.2024.18.3.0347
Publication history:
Received on 29 April 2024; revised on 08 June 2024; accepted on 11 June 2024
Abstract:
Inspite of the broadly available efficacious lipid-lowering drugs, atherosclerotic cardiovascular disease still remains a universal health issue. LDL-C represents an essential part in pathological process of atherosclerotic disease. High concentrations of plasma have been correlated with 50-70 % increase in progression of atherosclerotic plagues in patients with or without undistinguished cardiovascular risk. FDA has approved Novartis Leqvio (Inclisiran) first -in class siRNA to lower cholesterol and maintain it low with two doses a year. Inclisiran is a small interfering RNA (siRNA) molecule, targeting the hepatic production of PCSK9 results in lowering of LDL.
The review displays the current scientific information referring to inclisiran as a new favourable weapon in the control of hypercholesterolemia and insights to its global market forecast.
Keywords:
Atherosclerotic; Hypercholesterolemia; LDL-C; Inclisiran; siRNA; PCSK9; Global market
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0